A potential new use for ketamine, an FDA-regulated surgical anesthetic, has emerged—as a medication to help treat depressive disorders. What are the risks and benefits of ketamine as an antidepressant agent, particularly for individuals who have a substance use disorder? Join Hazelden Betty Ford’s chief medical officer Marvin D. Seppala, MD, to examine the research, pharmacology, controversies and considerations.
- Discuss clinical studies and research literature on ketamine as a treatment for major depression
- Identify risks and concerns associated with ketamine, especially for individuals with substance use disorders
- Gain information necessary for appropriate decision making regarding ketamine use for individuals with substance use disorders
Can't attend on the scheduled date?
Register and you'll receive notice when we post the recording for on-demand viewing.
A certificate of completion will be awarded for attending this event. Please note, this event has not been approved for continuing education (CE) credit. The participant is responsible to verify if this activity meets their continuing education board requirements in order to gain credit.
Psychiatrist, author and educator, Marvin D. Seppala, MD, serves as Hazelden Betty Ford’s chief medical officer. A nationally recognized expert in addiction recovery, pharmacological treatments for substance use disorders and integration of evidence-based practices, Dr. Seppala led Hazelden Betty Ford’s development of what has become the field’s leading treatment approach targeting opioid use disorder, Comprehensive Opioid Response with the Twelve Steps, COR-12®. Dr. Seppala also serves as adjunct assistant professor at both the Mayo Clinic College of Medicine and Science in the department of psychiatry and the Hazelden Betty Ford Graduate School of Addiction Studies.
15245 Pleasant Valley Rd, Center City, MN 55012